Switch theme
Sign up to access all valuation multiples
Yili Chuannig Biotechnology Co Ltd adopts the most advanced and mature international biological fermentation, chemical extraction, enzymatic hydrolysis, control and energy saving, and environmental protection technology. The main products of the company include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, and crude ursodeoxycholic acid.
2010
n/a
LTM Revenue $809M
LTM EBITDA $144M
$4.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Yili Chuannig Biotech has a last 12-month revenue (LTM) of $809M and a last 12-month EBITDA of $144M.
In the most recent fiscal year, Yili Chuannig Biotech achieved revenue of $799M and an EBITDA of $316M.
Yili Chuannig Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Yili Chuannig Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $809M | XXX | $799M | XXX | XXX | XXX |
| Gross Profit | $303M | XXX | $291M | XXX | XXX | XXX |
| Gross Margin | 37% | XXX | 36% | XXX | XXX | XXX |
| EBITDA | $144M | XXX | $316M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 40% | XXX | XXX | XXX |
| EBIT | $252M | XXX | $244M | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 30% | XXX | XXX | XXX |
| Net Profit | $203M | XXX | $194M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 24% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Yili Chuannig Biotech's stock price is CNY 13 (or $2).
Yili Chuannig Biotech has current market cap of CNY 28.9B (or $4.0B), and EV of CNY 29.1B (or $4.0B).
See Yili Chuannig Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.0B | $4.0B | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Yili Chuannig Biotech has market cap of $4.0B and EV of $4.0B.
Yili Chuannig Biotech's trades at 5.1x EV/Revenue multiple, and 12.8x EV/EBITDA.
Equity research analysts estimate Yili Chuannig Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Yili Chuannig Biotech has a P/E ratio of 19.7x.
See valuation multiples for Yili Chuannig Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.0B | XXX | $4.0B | XXX | XXX | XXX |
| EV (current) | $4.0B | XXX | $4.0B | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | 28.1x | XXX | 12.8x | XXX | XXX | XXX |
| EV/EBIT | 16.1x | XXX | 16.6x | XXX | XXX | XXX |
| EV/Gross Profit | 13.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.7x | XXX | 20.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 16.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialYili Chuannig Biotech's last 12 month revenue growth is 5%
Yili Chuannig Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Yili Chuannig Biotech's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Yili Chuannig Biotech's rule of X is 30% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Yili Chuannig Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 40% | XXX | XXX | XXX |
| EBITDA Growth | 152% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | 41% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 30% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yili Chuannig Biotech acquired XXX companies to date.
Last acquisition by Yili Chuannig Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Yili Chuannig Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Yili Chuannig Biotech founded? | Yili Chuannig Biotech was founded in 2010. |
| Where is Yili Chuannig Biotech headquartered? | Yili Chuannig Biotech is headquartered in China. |
| Is Yili Chuannig Biotech publicy listed? | Yes, Yili Chuannig Biotech is a public company listed on SHE. |
| What is the stock symbol of Yili Chuannig Biotech? | Yili Chuannig Biotech trades under 301301 ticker. |
| When did Yili Chuannig Biotech go public? | Yili Chuannig Biotech went public in 2022. |
| Who are competitors of Yili Chuannig Biotech? | Similar companies to Yili Chuannig Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Yili Chuannig Biotech? | Yili Chuannig Biotech's current market cap is $4.0B |
| What is the current revenue of Yili Chuannig Biotech? | Yili Chuannig Biotech's last 12 months revenue is $809M. |
| What is the current revenue growth of Yili Chuannig Biotech? | Yili Chuannig Biotech revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Yili Chuannig Biotech? | Current revenue multiple of Yili Chuannig Biotech is 5.0x. |
| Is Yili Chuannig Biotech profitable? | Yes, Yili Chuannig Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Yili Chuannig Biotech? | Yili Chuannig Biotech's last 12 months EBITDA is $144M. |
| What is Yili Chuannig Biotech's EBITDA margin? | Yili Chuannig Biotech's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Yili Chuannig Biotech? | Current EBITDA multiple of Yili Chuannig Biotech is 28.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
